JP2023078311A5 - - Google Patents

Download PDF

Info

Publication number
JP2023078311A5
JP2023078311A5 JP2023043678A JP2023043678A JP2023078311A5 JP 2023078311 A5 JP2023078311 A5 JP 2023078311A5 JP 2023043678 A JP2023043678 A JP 2023043678A JP 2023043678 A JP2023043678 A JP 2023043678A JP 2023078311 A5 JP2023078311 A5 JP 2023078311A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023043678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023078311A (ja
Filing date
Publication date
Priority claimed from JP2022531930A external-priority patent/JP7250219B2/ja
Application filed filed Critical
Publication of JP2023078311A publication Critical patent/JP2023078311A/ja
Publication of JP2023078311A5 publication Critical patent/JP2023078311A5/ja
Withdrawn legal-status Critical Current

Links

JP2023043678A 2020-06-19 2023-03-20 血管新生阻害剤と組み合わせて使用するための抗t細胞抗原結合分子 Withdrawn JP2023078311A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020106501 2020-06-19
JP2020106501 2020-06-19
JP2022531930A JP7250219B2 (ja) 2020-06-19 2021-06-18 血管新生阻害剤と組み合わせて使用するための抗t細胞抗原結合分子
PCT/JP2021/023149 WO2021256555A1 (ja) 2020-06-19 2021-06-18 血管新生阻害剤と組み合わせて使用するための抗t細胞抗原結合分子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022531930A Division JP7250219B2 (ja) 2020-06-19 2021-06-18 血管新生阻害剤と組み合わせて使用するための抗t細胞抗原結合分子

Publications (2)

Publication Number Publication Date
JP2023078311A JP2023078311A (ja) 2023-06-06
JP2023078311A5 true JP2023078311A5 (cg-RX-API-DMAC7.html) 2024-06-26

Family

ID=79268097

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022531930A Active JP7250219B2 (ja) 2020-06-19 2021-06-18 血管新生阻害剤と組み合わせて使用するための抗t細胞抗原結合分子
JP2023043678A Withdrawn JP2023078311A (ja) 2020-06-19 2023-03-20 血管新生阻害剤と組み合わせて使用するための抗t細胞抗原結合分子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022531930A Active JP7250219B2 (ja) 2020-06-19 2021-06-18 血管新生阻害剤と組み合わせて使用するための抗t細胞抗原結合分子

Country Status (15)

Country Link
US (1) US20230235056A1 (cg-RX-API-DMAC7.html)
EP (1) EP4186527A4 (cg-RX-API-DMAC7.html)
JP (2) JP7250219B2 (cg-RX-API-DMAC7.html)
KR (2) KR102594943B1 (cg-RX-API-DMAC7.html)
CN (1) CN115768478A (cg-RX-API-DMAC7.html)
AU (1) AU2021292932A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025536A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180951A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003622A1 (cg-RX-API-DMAC7.html)
CR (1) CR20230014A (cg-RX-API-DMAC7.html)
IL (1) IL299127A (cg-RX-API-DMAC7.html)
MX (1) MX2022015764A (cg-RX-API-DMAC7.html)
PE (1) PE20230435A1 (cg-RX-API-DMAC7.html)
TW (1) TW202214286A (cg-RX-API-DMAC7.html)
WO (1) WO2021256555A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
WO2025120867A1 (en) * 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202539742A (zh) * 2024-02-08 2025-10-16 大陸商上海翰森生物醫藥科技有限公司 抗體藥物偶聯物和抗vegf抗體的聯合應用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773719A (en) 1966-12-06 1973-11-20 Hoffmann La Roche 2-aminoxy-2'-acyl-acetanilide
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3431102A4 (en) * 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
WO2018038046A1 (ja) 2016-08-22 2018-03-01 中外製薬株式会社 ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物
EP3541843A1 (en) * 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP3600357A4 (en) * 2017-03-31 2021-01-06 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING

Similar Documents

Publication Publication Date Title
JP2023526975A5 (cg-RX-API-DMAC7.html)
JP2024036694A5 (cg-RX-API-DMAC7.html)
JP2024032941A5 (cg-RX-API-DMAC7.html)
JP2022122972A5 (cg-RX-API-DMAC7.html)
JP2023085489A5 (cg-RX-API-DMAC7.html)
JP2023105131A5 (cg-RX-API-DMAC7.html)
JP2025041734A5 (cg-RX-API-DMAC7.html)
JP2022185040A5 (cg-RX-API-DMAC7.html)
JP2023171775A5 (cg-RX-API-DMAC7.html)
JP2022184985A5 (cg-RX-API-DMAC7.html)
JP2023166402A5 (cg-RX-API-DMAC7.html)
JP2025069142A5 (cg-RX-API-DMAC7.html)
JP2024150466A5 (cg-RX-API-DMAC7.html)
JP2024026077A5 (cg-RX-API-DMAC7.html)
JP2023145572A5 (cg-RX-API-DMAC7.html)
JP2023052878A5 (cg-RX-API-DMAC7.html)
JP2023182571A5 (cg-RX-API-DMAC7.html)
JP2023133317A5 (cg-RX-API-DMAC7.html)
JP2023116477A5 (cg-RX-API-DMAC7.html)
JP2022064180A5 (cg-RX-API-DMAC7.html)
JP2020079331A5 (cg-RX-API-DMAC7.html)
JP2022518056A5 (cg-RX-API-DMAC7.html)
JP2025148617A5 (cg-RX-API-DMAC7.html)
JP2023012502A5 (cg-RX-API-DMAC7.html)
JP2022505925A5 (cg-RX-API-DMAC7.html)